Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7385882 | 0.88 | ACHE (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL12787597 | 0.86 | ACHE (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL31247911 | 0.86 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL26198817 | 0.86 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL26198816 | 0.86 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL11242696 | 0.85 | ACHE (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL9050615 | 0.84 | HRH4 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL10120804 | 0.83 | SMN1; SMN2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL9797316 | 0.82 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL29834112 | 0.82 | ACHE (0.54) | ACHEGLAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273566-A1 | NANOMATERIALS CONTAINING CONSTRAINED LIPIDS AND USES THEREOF | GEORGIA TECH RESEARCH CORP | 2022-09-01 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | CHRNB2 3321/4885CHRNB4 3326/4885CHRNA3 3459/4885 |
| US-20220273566-A1 | NANOMATERIALS CONTAINING CONSTRAINED LIPIDS AND USES THEREOF | CD47, SCARB1, LIPC | CHRNB2 4527/4885CHRNB4 4635/4885CHRNA3 4424/4885 |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | CHRNB2 4867/4885CHRNB4 4863/4885CHRNA3 4760/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | CHRNB2 4432/4885CHRNB4 4637/4885CHRNA3 4359/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | CHRNB2 4860/4885CHRNB4 4863/4885CHRNA3 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.